FibroGen (NASDAQ:FGEN) released its earnings results on Thursday. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.15, Fidelity Earnings reports. FibroGen had a negative net margin of 44.14% and a negative return on equity of 17.69%. The business had revenue of $23.90 million during the quarter, compared to analyst estimates of $20.44 million. During the same period in the prior year, the business earned ($0.50) earnings per share. The business’s quarterly revenue was down 25.1% on a year-over-year basis.
Shares of NASDAQ:FGEN traded down $9.28 during mid-day trading on Friday, hitting $36.39. The stock had a trading volume of 7,500,656 shares, compared to its average volume of 624,578. The company has a debt-to-equity ratio of 0.18, a quick ratio of 7.75 and a current ratio of 7.75. The company has a market cap of $3.93 billion, a PE ratio of -35.33 and a beta of 1.60. FibroGen has a 12-month low of $33.51 and a 12-month high of $68.55.
Several analysts recently commented on the stock. ValuEngine lowered shares of FibroGen from a “buy” rating to a “hold” rating in a research note on Friday. William Blair lowered shares of FibroGen from an “outperform” rating to a “market perform” rating in a research note on Friday. Mizuho reduced their price target on shares of FibroGen from $74.00 to $65.00 and set a “positive” rating for the company in a research report on Friday. Zacks Investment Research upgraded shares of FibroGen from a “hold” rating to a “strong-buy” rating and set a $55.00 price target for the company in a research report on Tuesday, April 30th. Finally, BidaskClub downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th. One analyst has rated the stock with a sell rating, three have given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $68.50.
In related news, CEO Thomas B. Neff sold 39,636 shares of the company’s stock in a transaction that occurred on Wednesday, February 20th. The shares were sold at an average price of $57.41, for a total value of $2,275,502.76. Following the completion of the sale, the chief executive officer now owns 2,658,056 shares in the company, valued at approximately $152,598,994.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Christine Chung sold 11,250 shares of the company’s stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $46.41, for a total transaction of $522,112.50. Following the completion of the sale, the senior vice president now owns 163,562 shares of the company’s stock, valued at approximately $7,590,912.42. The disclosure for this sale can be found here. In the last 90 days, insiders sold 231,791 shares of company stock valued at $12,644,356. 8.96% of the stock is owned by insiders.
FibroGen Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Read More: Balanced Fund
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.